INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 49 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $24,000 | +9.1% | 30,000 | +3.4% | 0.00% | – |
| Q2 2020 | $22,000 | -12.0% | 29,000 | -6.5% | 0.00% | -100.0% |
| Q1 2020 | $25,000 | -16.7% | 31,000 | +3.3% | 0.00% | 0.0% |
| Q4 2019 | $30,000 | +11.1% | 30,000 | -3.2% | 0.00% | 0.0% |
| Q3 2019 | $27,000 | -3.6% | 31,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $28,000 | 0.0% | 31,000 | +10.7% | 0.00% | 0.0% |
| Q1 2019 | $28,000 | -3.4% | 28,000 | -12.5% | 0.00% | 0.0% |
| Q4 2018 | $29,000 | -14.7% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q3 2018 | $34,000 | +17.2% | 34,000 | +3.0% | 0.00% | 0.0% |
| Q2 2018 | $29,000 | +11.5% | 33,000 | +3.1% | 0.00% | 0.0% |
| Q1 2018 | $26,000 | 0.0% | 32,000 | -5.9% | 0.00% | 0.0% |
| Q4 2017 | $26,000 | 0.0% | 34,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $26,000 | -31.6% | 34,000 | -12.8% | 0.00% | 0.0% |
| Q2 2017 | $38,000 | +5.6% | 39,000 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $36,000 | – | 39,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,324,000 | $4,995,000 | 3.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $53,020,000 | 2.12% |
| DLD Asset Management, LP | 32,500,000 | $30,048,000 | 2.06% |
| Castle Creek Arbitrage, LLC | 4,504,000 | $4,161,000 | 1.43% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 10,000,000 | $9,372,000 | 0.62% |
| Graham Capital Management, L.P. | 14,636,000 | $13,509,000 | 0.60% |
| OAKTREE CAPITAL MANAGEMENT LP | 64,452,000 | $59,704,000 | 0.54% |
| Context Capital Management, LLC | 1,000,000 | $926,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 23,118,000 | $21,341,000 | 0.52% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,583,000 | $17,322,000 | 0.21% |